Dashboard
1
Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months
- Poor long term growth as Operating profit has grown by an annual rate 4.66% of over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
Risky -
3
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
HKD 6,180 Million ()
20.00
NA
0.00%
0.10
-999,999.00%
2.77
Revenue and Profits:
Net Sales:
109 Million
(Quarterly Results - Dec 2012)
Net Profit:
62 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-30.24%
0%
-30.24%
6 Months
-40.65%
0%
-40.65%
1 Year
-0.67%
0%
-0.67%
2 Years
-37.76%
0%
-37.76%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Shandong Boan Biotechnology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.07%
EBIT Growth (5y)
4.66%
EBIT to Interest (avg)
-0.23
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.34
Sales to Capital Employed (avg)
45.84
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
4.94
EV to EBIT
-180.21
EV to EBITDA
-184.56
EV to Capital Employed
3.93
EV to Sales
22.47
PEG Ratio
0.38
Dividend Yield
NA
ROCE (Latest)
-2.18%
ROE (Latest)
24.31%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'12 - YoY
Dec'12
Dec'11
Change(%)
Net Sales
109.50
104.10
5.19%
Operating Profit (PBDIT) excl Other Income
61.90
-111.60
155.47%
Interest
21.40
33.00
-35.15%
Exceptional Items
-37.70
0.00
Consolidate Net Profit
61.80
152.30
-59.42%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2012 is 5.19% vs 23.49% in Dec 2011
Consolidated Net Profit
YoY Growth in quarter ended Dec 2012 is -59.42% vs -55.35% in Dec 2011
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
683.00
600.00
13.83%
Operating Profit (PBDIT) excl Other Income
-52.10
-263.50
80.23%
Interest
15.60
15.60
Exceptional Items
0.00
-50.20
100.00%
Consolidate Net Profit
-131.90
-385.80
65.81%
Operating Profit Margin (Excl OI)
-210.20%
-580.30%
37.01%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is 13.83% vs 213.64% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 65.81% vs -41.99% in Dec 2022
About Shandong Boan Biotechnology Co., Ltd. 
Shandong Boan Biotechnology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






